RADIANT-3 and RADIANT-4
The two trials that made everolimus a standard pill for pancreatic, lung and gut neuroendocrine tumours.
RADIANT-3: PFS 11.0 vs 4.6 months (HR 0.35); RADIANT-4: PFS 11.0 vs 3.9 months (HR 0.48). OS not significantly improved (crossover).
Setting
Progressive pancreatic NETs (RADIANT-3, n=410) and lung/GI NETs (RADIANT-4, n=302): everolimus vs placebo
Phase
Phase 3
Sponsor
Novartis
Registry
Headline result
PFS HR 0.35 (pNET) and 0.48 (lung/GI).
Reported
2011
Enrolled
712
In plain words
What these results mean for people, not percentages
Progression-free survival (RADIANT-3)primarysurrogate endpoint
- Median 11 vs 4.6 months with Everolimus compared with Placebo; about 6.4 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 65 percent lower chance of the event at any given time (hazard ratio 0.35, likely range 0.27 to 0.45).
Progression-free survival (RADIANT-4)primarysurrogate endpoint
- Median 11 vs 3.9 months with Everolimus compared with Placebo; about 7.1 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 52 percent lower chance of the event at any given time (hazard ratio 0.48, likely range 0.35 to 0.67).
Be careful
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Progressive pancreatic NETs (RADIANT-3, n=410) and lung/GI NETs (RADIANT-4, n=302): everolimus vs placebo. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
712 participants enrolled.
Progression-free survival (RADIANT-3)primary
HR 0.35 (0.27–0.45)
Everolimus
11 mo
Placebo
4.6 mo
Progression-free survival (RADIANT-4)primary
HR 0.48 (0.35–0.67)
Everolimus
11 mo
Placebo
3.9 mo
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (RADIANT-3)primary | Everolimus | 207 | 11 months | 0.35 (0.27–0.45) | — | — |
| Placebo | 203 | 4.6 months | ||||
| Progression-free survival (RADIANT-4)primary | Everolimus | 205 | 11 months | 0.48 (0.35–0.67) | — | — |
| Placebo | 97 | 3.9 months |
Pages like this
not linked directly; found by shared links- TrialCOMPETE
Shares Everolimus, Neuroendocrine tumours.
- TargetAKT
Shares Everolimus, Neuroendocrine tumours.